Aegis thinks Alcobra can double in 2014

|About: Alcobra Ltd. (ADHD)|By:, SA News Editor

Alcobra (ADHD +1.3%) is a top pick for 2014 at Aegis.

"In our view, MG01CI could have a best- in-class efficacy profile for treatment of PI-ADHD, which comprises over 40% of all ADHD sufferers," analyst Raghuram Selvaraju says, adding that the Orphan Designation in FXS "confers seven years of automatic market exclusivity and a rapid path to commercialization on MG01CI early in its development process as an FXS drug."

Price target is $40, which represents upside of 122% from Tuesday's close.

For more on MG01CI in FXS, see here.